3.1. Participants
The participants were recruited from 7 to 22 September 2022. In total, 40 healthy adults were enrolled; 20 were assigned to sequence A (bLF first) and the others were assigned to sequence B (placebo first). Overall, 3 participants dropped out due to consent withdrawal and 37 completed the test. In total, 3 other participants were excluded for meeting the exclusion criteria (UWSFR < 0.1 mL/min), leaving 34 for the per-protocol analysis (